Genetic Technologies (ASX:GTG) Current Accrued Expense: A$0.38 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Current Accrued Expense?

Genetic Technologies ASX:GTG Current Accrued Expense is A$0.38 Mil as of Jun. 2024.

Genetic Technologies's Current Accrued Expense for the quarter that ended in Jun. 2024 was A$0.38 Mil.

Genetic Technologies's quarterly Current Accrued Expense stayed the same from Dec. 2023 (A$0.00 Mil) to Mar. 2024 (A$0.00 Mil) but then increased from Mar. 2024 (A$0.00 Mil) to Jun. 2024 (A$0.38 Mil).

Genetic Technologies's annual Current Accrued Expense increased from Jun. 2022 (A$0.01 Mil) to Jun. 2023 (A$0.62 Mil) but then declined from Jun. 2023 (A$0.62 Mil) to Jun. 2024 (A$0.38 Mil).

Genetic Technologies Current Accrued Expense Related Terms

Genetic Technologies Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Current Accrued Expense Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.49 0.01 0.62 0.38

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.38 0.00

Genetic Technologies Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of A$0.38 Mil mean?
Genetic Technologies (ASX:GTG) has a Current Accrued Expense of A$0.38 Mil as of Jun. 2024. Current Accrued Expense records the total amount of accrued expenses. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Current Accrued Expense too high?
Genetic Technologies' current Current Accrued Expense is A$0.38 Mil.
How does Genetic Technologies' Current Accrued Expense compare to LDDD and NOTV?
Genetic Technologies' Current Accrued Expense of A$0.38 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Genetic Technologies and its competitors. Genetic Technologies's current Current Accrued Expense is A$0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Current Accrued Expense of A$0.38 Mil. The current Current Accrued Expense is A$0.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Current Accrued Expense is A$0.38 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.